Stock Evaluator: BioLineRx Ltd. (BLRX)

BioLineRx Ltd. BLRX

$2.51 -0.06 -2.32%
September 11, 2026 4:00:00 PM EST November 10, 2021 Volume: 9,539
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Commentary & Analysis


Financial Summary

Share Statistics BLRX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $11.2 $269.3 7%
Shares Out (Mil) 2,664.8 54.0 98%
Institutional Ownership 91.8% 93.0% 60%
Float (Mil) 2,464.0 42.2 96%
Beta 0.70 0.95 41%
Avg Daily Volume (000s) 46 473 28%
Price Change
(52-week)
(40.8%) 55.9% 20%
Growth BLRX Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 14.1% na
Net Income (5yr) 47.5% (10.1%) 93%
EPS (5yr) 14.9% 15.7% 55
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) (14.9%) (15.6%) 53%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na 1 1
Current EPS $0.000 ($3.140) ($2.520)
Month Ago EPS na na na
# Rev Up 0 0 1
# Rev Down 1 1 0
Three Months Ago EPS ($0.300) ($0.930) ($0.640)
Year/Year Chg (100.0%) na na
Financials BLRX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $1 $37 2%
Net Income (TTM) (Mil) ($7) ($43) 31%
EPS (TTM) ($0.003) ($1.500) 39%
Operating Cash Flow (TTM) (Mil) ($11) ($31) 19%
Net Cash Flow (TTM) (Mil) ($3) $2 37%
Long-Term Debt (Q1) (Mil) $3 $4 22%
Enterprise Value (Q1) (Mil) $10 $182 7%
Valuation BLRX Industry
Median
Percentile
(All Stocks)
P/B 251.00 2.62 100%
P/E na 19.4 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.0 na
Ratios BLRX Industry
Median
Percentile
(All Stocks)
Gross Margin 80.0% 67.6% 89%
Net Margin (502.1%) (73.5%) 2%
ROA (18.2%) (47.9%) 21%
ROE (41.3%) (55.0%) 17%
Liabilities to Assets 50.4% 29.5% 43%
F-Score 2 3 7%

BioLineRx Ltd. did not pass any screens on 9/11/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors